<DOC>
	<DOCNO>NCT02377206</DOCNO>
	<brief_summary>The purpose study assess level neuroinflammation Alzheimer Disease subject ( mild moderate ) estimate Binding Potential ( BP ) [ 18F ] DPA-714 , relationship kinetics cognitive decline 24-month follow-up period ( assessed Alzheimer 's Disease Assessment Scale-cognitive subscale ( ADAS-Cog ) Mini-Mental State Examination ( MMSE ) score ) .</brief_summary>
	<brief_title>Neuroinflammation Cognitive Decline Alzheimer Disease</brief_title>
	<detailed_description>The purpose study assess level neuroinflammation Alzheimer Disease subject ( mild moderate ) estimate Binding Potential ( BP ) [ 18F ] DPA-714 , relationship kinetics cognitive decline 24-month follow-up period ( assessed ADAS-Cog MMSE score ) . ( DPA-714 : N , N-diethyl-2- [ 4- ( 2-fluoroethoxy ) phenyl ] -5,7-dimethylpyrazolo [ 1,5-a ] pyrimidine-3-acetamide )</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Cognition Disorders</mesh_term>
	<criteria>Informed consent Age 60 85 year ( include ) necessary knowledge French ( write oral ) neuropsychological test Study level upper ( equal ) 7 year ( consider first year grammarschool start ) People Alzheimer Disease define National Institute Neurological Communicative Disorders Stroke ( NINCDS ) Alzheimer 's Disease Related Disorders Association ( ADRDA ) standard : Light mild AD define MiniMental State Examination ( MMSE ) score 15 25 ( include ) Social security affiliation . MMSE score low 15 upper equal 26 Evolutive disease could possibly consequences central nervous system Inflammatory disease evolutive neoplasia and/or C reactive protein ( CRP ) upper 10mg/L Chronic use alchohol and/or drug Serious depression define Montgomery Asberg Depression Rating Scale ( MADRS ) score high 18 Surgical medical condition last 3 month Long term treatment could possibly interfere inflammatory process ( especially month PET [ 18F ] DPA714 imaging ) . Treatment NMethylDAspartate antagonist Treatment Minocycline Treatment benzodiazepine ( especially month PET [ 18F ] DPA714 imaging ) ( Zolpidem , zopiclone loprazolam except ) Anomaly neurological examination classical symptom Contraindication magnetic resonance imaging ( RMI ) Florbetapir [ 18F ] hypersensibility Participation experimental protocol drug . people guardianship</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>PET</keyword>
	<keyword>[ 18F ] DPA-714</keyword>
	<keyword>cognitive decline</keyword>
</DOC>